Study summary
Ulixacaltamide became the first new tremor pill to succeed in phase 3
4.3point better daily-living score than placebo at 8 weeks
What was tested
Ulixacaltamide, a pill that blocks T-type calcium channels in tremor circuits, against placebo in two phase 3 trials run largely remotely.
What they found
- Daily-living scores improved 4.3 points more than with placebo at week 8.
- Many people stopped the drug, mainly for dizziness and brain fog; reported rates vary by source.
- The FDA granted Breakthrough Therapy designation and Praxis submitted a new drug application.
What it means
Could be the first drug approved specifically for essential tremor in decades; tolerability will matter.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.